Title: Riguo Fang: Innovator in Hematopoietic Stem Cell Research
Introduction: Riguo Fang is an accomplished inventor based in Beijing, China. He is currently associated with Edigene Inc., where he focuses on advancements in hematopoietic stem cell research. Despite having no granted patents to his name, his contributions to the field are noteworthy.
Latest Patent Applications: Riguo Fang has been involved in several significant patent applications. One of his latest applications is titled "Culture Medium Composition for Amplifying and Maintaining Self-Renewal Capacity and Differentiation Potential of HSCs and Application Thereof." This application details a culture medium composition designed to expand hematopoietic stem cells (HSCs) while preserving their self-renewal capacity and differentiation potential. The composition includes a hematopoietic stem cell medium and a small molecule inhibitor of a PDGFR target, which significantly enhances HSC expansion during in-vitro culture.
Another notable application is "Use of Compound for Improving Transplantation Efficiency of Human Hematopoietic Stem Cells." This application discusses the use of various compounds, including tubulin polymerization inhibitors and specific chemical agents, to improve the transplantation efficiency of human HSCs. The compounds enhance the expression of the hematopoietic stem cell surface protein CD184, thereby improving the migration and homing abilities of HSCs in the bone marrow microenvironment.
Conclusion: Riguo Fang's innovative work in hematopoietic stem cell research demonstrates his commitment to advancing medical science. His latest patent applications reflect his dedication to improving transplantation efficiency and maintaining the vital characteristics of stem cells.